Although the current first-line antiviral therapies, Nucleos(t)ide Analogues (NAs) and Pegylated Interferon-alpha (PEG-IFNα), are effective in suppressing viral replication and slowing the progression of cirrhosis and hepatocellular carcinoma (HCC), functional cure rates (defined as sustained HBsAg clearance) remain below 10%, and most patients require lifelong treatment or experience poor tolerability (Wu et al., 2025; Yuen et al., 2018). This evidence concerns the gene IFNA1 and hepatocellular carcinoma.